Details for Patent: 9,074,255
Which drugs does patent 9,074,255 protect, and when does it expire?
Patent 9,074,255 protects BYSANTI and FANAPT and is included in two NDAs.
This patent has five patent family members in four countries.
Summary for Patent: 9,074,255
| Title: | Method of predicting a predisposition to QT prolongation |
| Abstract: | The present invention describes an association between genetic polymorphisms in the FAM13A1 (family with sequence similarity 13, member A1) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval- prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation. |
| Inventor(s): | Christian Lavedan, Simona Volpi, Louis Licamele |
| Assignee: | Vanda Pharmaceuticals Inc |
| Application Number: | US13/263,075 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,074,255 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 9,074,255
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vanda Pharms Inc | BYSANTI | milsaperidone | TABLET;ORAL | 220358-001 | Feb 20, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | METHOD FOR ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN ADULTS BY ADMINISTERING MILSAPERIDONE TO A PATIENT BY LOWERING THE DOSE AFTER DETERMINING THAT THE PATIENT HAS A GENETIC PREDISPOSITION FOR QT PROLONGATION | ⤷ Start Trial | ||||
| Vanda Pharms Inc | BYSANTI | milsaperidone | TABLET;ORAL | 220358-001 | Feb 20, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | METHOD FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTERING MILSAPERIDONE TO A PATIENT BY LOWERING THE DOSE AFTER DETERMINING THAT THE PATIENT HAS A GENETIC PREDISPOSITION FOR QT PROLONGATION | ⤷ Start Trial | ||||
| Vanda Pharms Inc | BYSANTI | milsaperidone | TABLET;ORAL | 220358-002 | Feb 20, 2026 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | METHOD FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTERING MILSAPERIDONE TO A PATIENT BY LOWERING THE DOSE AFTER DETERMINING THAT THE PATIENT HAS A GENETIC PREDISPOSITION FOR QT PROLONGATION | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,074,255
| PCT Information | |||
| PCT Filed | April 05, 2010 | PCT Application Number: | PCT/US2010/029931 |
| PCT Publication Date: | October 14, 2010 | PCT Publication Number: | WO2010/117937 |
International Family Members for US Patent 9,074,255
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 2757717 | ⤷ Start Trial | |||
| European Patent Office | 2417266 | ⤷ Start Trial | |||
| Japan | 2012522533 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
